A Large and Growing Market, Driven by Structural Tailwinds
- Global compounding market size Source: Vision Research Reports**
- €13.2bn
- Projected CAGR 2024–2030**
- ~5.1%
- Estimated market size by 2030**
- €18bn
Market Opportunity
Growing market opportunities driven by personalized treatment demand.
Standard commercial medicines are designed to work for most patients. Pharmaceutical compounding exists to serve the rest; delivering treatments tailored to individual clinical needs that the broader market simply cannot accommodate. It is a well-established, growing segment of global healthcare, and the investment case for the market’s leading operator is compelling. Compounded medications represent approximately 1.5% * of all prescriptions worldwide, a market currently valued at around €13.2 billion ** and forecast to reach €18 billion ** by 2030.
* Own company estimate. ** According to independent research (Vision Research Reports)
Five Structural Drivers
Aging Population
Rising life expectancy and increasing chronic disease prevalence are expanding the need for individualized treatments. Pain management, infusion therapies, and home-based care, all significant growth areas within compounding are each tied to aging demographics and the ongoing shift toward decentralized healthcare delivery.
Personalization of Medicine
Standard commercial formulations cannot accommodate every patient’s clinical needs. Compounding addresses this gap by creating tailored treatments that account for allergies, dosage precision, administration route, and tolerability. Fagron Genomics further extends this capability, enabling healthcare providers to link genetic profiles to optimized therapeutic outcomes.
Prevention and Lifestyle
A growing global middle class, increased health awareness, and advances in genomics are accelerating demand for preventive and functional medicine. The ability to build detailed genetic and metabolic profiles is transforming how treatments are designed, shifting the conversation from disease management to personalized health optimization.
Drug Shortages and Access
Pharmaceutical compounding plays a critical role when commercially available medications are unavailable or inadequate. Drug shortages are a persistent feature of the global medicines supply chain and are accelerating the trend toward outsourcing to specialist compounders. Fagron’s infrastructure and product breadth position it to respond with speed and reliability.
Regulatory Complexity as a Barrier to Entry
Increasing regulatory standards are pushing pharmacies and hospitals to outsource compounding to specialized, compliant providers. This regulatory tailwind raises the bar for participation in the market and structurally advantages established, scaled operators like Fagron.